<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Salix Pharmaceuticals Limited</title>
	<atom:link href="http://www.stockbloghub.com/tag/salix-pharmaceuticals-limited/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(DRE) Duke Realty Leases to Novella</title>
		<link>http://www.stockbloghub.com/2012/05/20/dre-duke-realty-leases-to-novella/100326</link>
		<comments>http://www.stockbloghub.com/2012/05/20/dre-duke-realty-leases-to-novella/100326#comments</comments>
		<pubDate>Sun, 20 May 2012 20:16:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[REIT - Diversified]]></category>
		<category><![CDATA[Claymore-Zacks Country Rotation]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[DRE]]></category>
		<category><![CDATA[Duke Realty Corporation]]></category>
		<category><![CDATA[Host Hotels & Resorts Inc.]]></category>
		<category><![CDATA[HST]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=100326</guid>
		<description><![CDATA[Duke Realty Corp. (DRE), a real estate investment trust (REIT), recently signed an agreement with Novella Clinical to lease a property in North Carolina, located at 1700 Perimeter Park Drive in Morrisville. The financial terms of the agreement were not divulged. Novella Clinical Inc. is a full service clinical research organization (CRO) having dual headquarters in Research Triangle Park, N.C. and Stevenage, England. The company primarily caters to the oncology, medical device and biopharmaceutical industries. The 1700 Perimeter Park Drive building is a three storey Class A office building spanning 77,239 square feet. The property was previously occupied by Salix Pharmaceuticals ltd. (SLXP). The 2.5 million square feet Perimeter Park is a mixed-use development property comprising a park-like setting. It includes office and industrial space along with hospitality, medical, fitness, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/05/20/dre-duke-realty-leases-to-novella/100326/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/11/28/slxp-salix-pharmaceuticals-bull-of-the-day-2/87621</link>
		<comments>http://www.stockbloghub.com/2011/11/28/slxp-salix-pharmaceuticals-bull-of-the-day-2/87621#comments</comments>
		<pubDate>Mon, 28 Nov 2011 20:44:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87621</guid>
		<description><![CDATA[Salix Pharmaceuticals (SLXP) third quarter results exceeded expectations with higher revenues boosting performance. With the company raising its revenue guidance, we have raised our estimates as well. Salix is well-positioned for growth in the gastrointestinal market. We believe lead product Xifaxan will continue to experience solid, above-market trend growth given its safety profile and lack of systemic absorption. We were pleased to see Xifaxan gain approval for the hepatic encephalopathy indication, as we believe that the main potential for Salix lies in gaining approval for additional indications for Xifaxan. Meanwhile, we are pleased to see the company expanding its pipeline through in-licensing deals and acquisitions. We expect the company to continue pursuing suitable in-licensing opportunities in order to grow revenues. We believe the current price represents an attractive entry point ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/slxp-salix-pharmaceuticals-bull-of-the-day-2/87621/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/11/28/slxp-salix-pharmaceuticals-bull-of-the-day/87587</link>
		<comments>http://www.stockbloghub.com/2011/11/28/slxp-salix-pharmaceuticals-bull-of-the-day/87587#comments</comments>
		<pubDate>Mon, 28 Nov 2011 15:58:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87587</guid>
		<description><![CDATA[Salix Pharmaceuticals (SLXP) third quarter results exceeded expectations with higher revenues boosting performance. With the company raising its revenue guidance, we have raised our estimates as well. Salix is well-positioned for growth in the gastrointestinal market. We believe lead product Xifaxan will continue to experience solid, above-market trend growth given its safety profile and lack of systemic absorption. We were pleased to see Xifaxan gain approval for the hepatic encephalopathy indication, as we believe that the main potential for Salix lies in gaining approval for additional indications for Xifaxan. Meanwhile, we are pleased to see the company expanding its pipeline through in-licensing deals and acquisitions. We expect the company to continue pursuing suitable in-licensing opportunities in order to grow revenues. We believe the current price represents an attractive entry point ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/slxp-salix-pharmaceuticals-bull-of-the-day/87587/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Analyst Maintains Neutral</title>
		<link>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351</link>
		<comments>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351#comments</comments>
		<pubDate>Wed, 06 Jul 2011 00:16:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78351</guid>
		<description><![CDATA[We have maintained a Neutral rating on Optimer Pharmaceuticals, Inc. (OPTR) with a target price of $12.00 per share. We find the US Food and Drug Administration’s (FDA) approval of Optimer’s first drug, antibiotic Dificid, for the treatment of clostridium difficile-associated diarrhea (CDAD), highly encouraging. CDAD is the most common nosocomial or hospital-acquired diarrhea and is a significant malaise in hospitals and nursing home facilities. Dificid (twice daily tablets) is the first drug to be approved in almost 30 years for the treatment of CDAD. Dificid is the only drug which has shown superiority over ViroPharma’s (VPHM) Vancocin &#8211; the only other FDA approved antibiotic for the treatment of clostridium difficile infection &#8211; in sustaining clinical response for CDAD. The superior recurring benefits of Dificid over Vancocin will be included ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/optr-optimer-pharmaceuticals-analyst-maintains-neutral/78351/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharma Beats on One-Time Gain</title>
		<link>http://www.stockbloghub.com/2011/05/10/optr-optimer-pharma-beats-on-one-time-gain/73730</link>
		<comments>http://www.stockbloghub.com/2011/05/10/optr-optimer-pharma-beats-on-one-time-gain/73730#comments</comments>
		<pubDate>Wed, 11 May 2011 05:28:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73730</guid>
		<description><![CDATA[Optimer Pharma’s (OPTR) first quarter 2011 earnings of $1.14 per share tellingly reversed the year-ago loss of 39 cents per share and exceeded the Zacks Consensus Estimate of 30 cents. The earnings beat was due to a huge increase in the top-line in the reported quarter. In the first quarter, revenues were $69.3 million versus $0.30 million in the prior-year quarter. Optimer does not have any marketed products at present. The substantial year-over-year growth was due to the receipt of a one-time $69.2 million upfront payment from Astellas Pharma in exchange for development and commercialization rights for fidaxomicin in certain territories outside US. Fidaxomicin is Optimer’s primary drug candidate which is currently under review both in the US and Europe for the treatment of Clostridium difficile infection (CDI). Fidaxomicin will ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/10/optr-optimer-pharma-beats-on-one-time-gain/73730/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Partners With Cubist Pharmaceuticals for Dificid</title>
		<link>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-partners-with-cubist-pharmaceuticals-for-dificid/70927</link>
		<comments>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-partners-with-cubist-pharmaceuticals-for-dificid/70927#comments</comments>
		<pubDate>Thu, 07 Apr 2011 17:24:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70927</guid>
		<description><![CDATA[Optimer Pharmaceuticals Inc. (OPTR) recently announced an exclusive two-year agreement with Cubist Pharmaceuticals Inc. (CBST) to co-promote its lead pipeline candidate, fidaxomicin, to be sold as Dificid in the US. The collaboration follows on the heels of a US panel backing for Dificid for the treatment of Clostridium difficile infection (CDI), which is also known as Clostridium difficile-associated diarrhea (CDAD). The FDA decision on Dificid is expected in May 2011. The candidate is also under regulatory review in the EU. Per the terms of the deal, Optimer will book sales on the candidate, if approved. Optimer also retains the new drug application (NDA) for Dificid. It will also be responsible for FDA approval and manufacturing of the candidate. In exchange for its efforts in co-promoting Dificid, Cubist will be entitled ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-partners-with-cubist-pharmaceuticals-for-dificid/70927/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Earns FDA Panel Nod on Dificid Drug</title>
		<link>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-earns-fda-panel-nod-on-dificid-drug/70818</link>
		<comments>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-earns-fda-panel-nod-on-dificid-drug/70818#comments</comments>
		<pubDate>Thu, 07 Apr 2011 14:10:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70818</guid>
		<description><![CDATA[Optimer Pharmaceuticals Inc. (OPTR) received a major boost when an advisory panel of the US Food and Drug Administration (FDA) unanimously recommended approval of its lead pipeline candidate, Dificid (fidaxomicin), for the treatment of Clostridium difficile infection (CDI) and for reducing the risk of recurrence when used for treatment of initial CDI. CDI is the most common nosocomial or hospital-acquired diarrhea. The Anti-Infective Drugs Advisory Committee (AIDAC) voted 13-0 to recommend approval of the candidate believing that it was safe and efficacious in the treatment of CDI. The positive recommendation was based on combined data from two late-stage studies, which revealed that Dificid was superior to ViroPharma’s (VPHM) Vancocin (the only FDA approved antibiotic for the treatment of CDI) in reducing CDI recurrence by 47%. The data further revealed improved ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/07/optr-optimer-pharmaceuticals-earns-fda-panel-nod-on-dificid-drug/70818/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals Posts Narrower Third Quarter 2010 Loss</title>
		<link>http://www.stockbloghub.com/2010/11/17/slxp-salix-pharmaceuticals-posts-narrower-third-quarter-2010-loss/59433</link>
		<comments>http://www.stockbloghub.com/2010/11/17/slxp-salix-pharmaceuticals-posts-narrower-third-quarter-2010-loss/59433#comments</comments>
		<pubDate>Thu, 18 Nov 2010 05:19:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59433</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) posted a loss of 5 cents per share in the third quarter of 2010, narrower than the Zacks Consensus Estimate of a loss of 15 cents and the guidance provided by the company (loss of 13 cents). Salix had reported a loss of 15 cents in the year-ago quarter. Higher revenues helped the company post a narrower loss in the reported quarter. Third quarter revenues increased 22.8% to $80.6 million, mainly due to strong Xifaxan sales. Revenues were well above the company’s guidance of $73 million and the Zacks Consensus Estimate of $76 million. Quarter in Detail Salix’ third quarter performance was driven by its key product Xifaxan, which posted sales of $65.2 million, up 53%. Prescriptions grew 65% during the third quarter. Salix reported that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/17/slxp-salix-pharmaceuticals-posts-narrower-third-quarter-2010-loss/59433/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OPTR) Optimer Pharmaceuticals Signs Manufacturing Deal</title>
		<link>http://www.stockbloghub.com/2010/05/25/optr-optimer-pharmaceuticals-signs-manufacturing-deal/38389</link>
		<comments>http://www.stockbloghub.com/2010/05/25/optr-optimer-pharmaceuticals-signs-manufacturing-deal/38389#comments</comments>
		<pubDate>Tue, 25 May 2010 22:15:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CDI]]></category>
		<category><![CDATA[CDI Corporation]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SLXP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=38389</guid>
		<description><![CDATA[Recently, Optimer Pharmaceuticals (OPTR) entered into a long-term supply agreement with India based Biocon Limited. The agreement is aimed at manufacturing the active pharmaceutical ingredient of fidaxomicin, Optimer’s lead candidate. Fidaxomicin is being developed to treat Clostridium difficile infection (CDI), the most common nosocomial or hospital-acquired, diarrhea. Following positive results from the second phase III trial of the drug in February 2010, Optimer is preparing to submit a new drug application in the second half of 2010. We believe the agreement with Biocon is a step towards the preparatory groundwork. While Optimer currently holds worldwide rights to fidaxomicin, it is on the lookout for a suitable partnership for the commercialization of fidaxomicin outside North America. Optimer also plans to submit a Marketing Authorization Application (MAA) for fidaxomicin with the European ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/25/optr-optimer-pharmaceuticals-signs-manufacturing-deal/38389/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals Exceeds Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2010/05/17/slxp-salix-pharmaceuticals-exceeds-consensus-estimates/37432</link>
		<comments>http://www.stockbloghub.com/2010/05/17/slxp-salix-pharmaceuticals-exceeds-consensus-estimates/37432#comments</comments>
		<pubDate>Mon, 17 May 2010 22:26:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37432</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) reported a net loss of 45 cents per share in the first quarter of 2010, 6 cents better than the Zacks Consensus Estimate. The company had guided towards a net loss of 50 cents. Salix reported a net loss of 29 cents in the year-ago period. Net loss increased from the year-ago period mainly due to an increase in costs and a slight decline in revenues. First quarter revenues declined slightly (1.6%) to $44.1 million, mainly due to decreased unit sales of MoviPrep, OsmoPrep, Apriso and Pepcid. This was partially offset by increased unit sales of Xifaxan and price increases. Xifaxan sales increased 23.9% to $29.9 million with prescription demand growing 15% during the quarter. The bowel cleansing franchise, consisting of MoviPrep and OsmoPrep generated revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/17/slxp-salix-pharmaceuticals-exceeds-consensus-estimates/37432/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals Earns FDA Approval for Xifaxan</title>
		<link>http://www.stockbloghub.com/2010/03/29/slxp-salix-pharmaceuticals-earns-fda-approval-for-xifaxan/31997</link>
		<comments>http://www.stockbloghub.com/2010/03/29/slxp-salix-pharmaceuticals-earns-fda-approval-for-xifaxan/31997#comments</comments>
		<pubDate>Mon, 29 Mar 2010 17:49:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31997</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) received a huge boost recently with the US approval of Xifaxan 550 mg. The Food and Drug Administration (FDA) granted approval for the use of Xifaxan 550 mg in reducing the risk of the recurrence of overt hepatic encephalopathy (HE) in adult patients. The approval was in-line with expectations as the drug had received a favorable recommendation from the FDA’s Gastrointestinal Drugs Advisory Committee in Feb 2010. The additional indication for the drug is a major positive for Salix. Xifaxan is currently the primary growth driver at Salix following the entry of generic versions of Colazal in December 2007. Xifaxan (200 mg) is indicated for the treatment of patients 12 years of age and older with ‘travelers diarrhea’ caused by non-invasive strains of E coli. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/slxp-salix-pharmaceuticals-earns-fda-approval-for-xifaxan/31997/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals Beats Forecasts but Outlook Disappoints</title>
		<link>http://www.stockbloghub.com/2010/03/10/slxp-salix-pharmaceuticals-beats-forecasts-but-outlook-disappoints/30236</link>
		<comments>http://www.stockbloghub.com/2010/03/10/slxp-salix-pharmaceuticals-beats-forecasts-but-outlook-disappoints/30236#comments</comments>
		<pubDate>Wed, 10 Mar 2010 20:17:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30236</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) reported a net loss of 13 cents per share in the fourth quarter, a penny better than the Zacks Consensus Estimate and company guidance of a net loss of 14 cents. Salix reported a net loss of 12 cents in the year-ago period. Higher product sales helped the company beat expectations despite an increase in costs. Full year net loss came in at 88 cents, a penny better than the Zacks Consensus Estimate and flat from the year-ago net loss. Revenues increased 30.3% to $232.9 million in 2009. Fourth quarter revenues increased 16% to $70.2 million, with Xifaxan sales increasing 4.6% to $24.9 million. The bowel cleansing franchise, consisting of MoviPrep, Visicol and OsmoPrep generated fourth quarter revenues of $30.4 million, up 54% from the year-ago ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/10/slxp-salix-pharmaceuticals-beats-forecasts-but-outlook-disappoints/30236/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals Focuses on Label Expansion</title>
		<link>http://www.stockbloghub.com/2010/03/08/slxp-salix-pharmaceuticals-focuses-on-label-expansion/29955</link>
		<comments>http://www.stockbloghub.com/2010/03/08/slxp-salix-pharmaceuticals-focuses-on-label-expansion/29955#comments</comments>
		<pubDate>Mon, 08 Mar 2010 15:52:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29955</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) is slated to report fourth quarter as well as fiscal 2009 results on March 9. The current Zacks Consensus Estimate for the fourth quarter of 2009 is a loss of 14 cents. For the full year, the Zacks Consensus Estimate stands at a loss of 89 cents. Salix suffered a major setback in Dec 2007 when its lead product, Colazal, started facing generics from several companies including Mylan (MYL). The genericization of Colazal adversely impacted the company’s top-and bottom-line. Since then, Salix has been working on reviving growth and is now focusing on gaining additional indications for its current growth driver, Xifaxan (rifaximin). More than earnings, we believe that investor focus will remain on the company’s success in gaining approval for additional indications of Xifaxan. Salix ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/08/slxp-salix-pharmaceuticals-focuses-on-label-expansion/29955/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals Gets Good News From FDA</title>
		<link>http://www.stockbloghub.com/2010/03/01/slxp-salix-pharmaceuticals-gets-good-news-from-fda/29391</link>
		<comments>http://www.stockbloghub.com/2010/03/01/slxp-salix-pharmaceuticals-gets-good-news-from-fda/29391#comments</comments>
		<pubDate>Mon, 01 Mar 2010 23:34:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29391</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) received good news recently when the Food and Drug Administration&#8217;s (FDA) Gastrointestinal Drugs Advisory Committee recommended the approval of Xifaxan (500 mg) for the maintenance of remission of hepatic encephalopathy (HE). Xifaxan is currently the primary growth driver at Salix following the entry of generic versions of Colazal in December 2007. Xifaxan (200 mg) is indicated for the treatment of patients 12 years of age and older with traveler&#8217;s diarrhea caused by non-invasive strains of E coli. Approval for the HE indication would be a major boost for the company. The Committee voted 14 &#8211; 4 in favor of approval. While the FDA is not required to follow the Committee&#8217;s recommendation, it usually does so. A response from the FDA should be out by March 24, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/01/slxp-salix-pharmaceuticals-gets-good-news-from-fda/29391/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals to File for IBS Indication</title>
		<link>http://www.stockbloghub.com/2009/12/16/slxp-salix-pharmaceuticals-to-file-for-ibs-indication/23023</link>
		<comments>http://www.stockbloghub.com/2009/12/16/slxp-salix-pharmaceuticals-to-file-for-ibs-indication/23023#comments</comments>
		<pubDate>Wed, 16 Dec 2009 22:54:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hawaiian Electric Industries Inc]]></category>
		<category><![CDATA[HE]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23023</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) recently held a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) related to the company’s new drug application (NDA) for rifaximin for the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS). The meeting was conducted to discuss the completion of the company’s non-C IBS development program, the results of two phase III studies (TARGET 1 and TARGET 2), and to reach agreement on the content and format of the company’s NDA for the indication. TARGET 1 and TARGET 2 were conducted to evaluate the efficacy and safety of rifaximin 550 mg. Results showed that patients treated with rifaximin achieved a statistically significant improvement in the primary endpoint compared to placebo treated patients. Rifaximin also achieved statistical significance in the key secondary endpoint ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/slxp-salix-pharmaceuticals-to-file-for-ibs-indication/23023/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLXP) Salix Pharmaceuticals Beats Expectation on Xifaxan&#8217;s Strength</title>
		<link>http://www.stockbloghub.com/2009/11/12/slxp-salix-pharmaceuticals-beats-expectation-on-xifaxans-strength/20386</link>
		<comments>http://www.stockbloghub.com/2009/11/12/slxp-salix-pharmaceuticals-beats-expectation-on-xifaxans-strength/20386#comments</comments>
		<pubDate>Thu, 12 Nov 2009 16:19:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Salix Pharmaceuticals Limited]]></category>
		<category><![CDATA[SLXP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20386</guid>
		<description><![CDATA[Salix Pharmaceuticals, Ltd. (SLXP) reported a net loss of 15 cents per share in the third quarter, which was significantly better than the Zacks Consensus Estimate of a net loss of 29 cents. The company reported a net loss of 11 cents in the year-ago period. Although revenue increased from the year-ago period, higher operating expenses led to the year-over-year increase in net loss. Total product revenue was $65.7 million, up 53%. Xifaxan continued to perform well with revenue almost doubling to $42.7 million. We believe wholesaler stocking, price increases and prescription growth were responsible for the significant increase in Xifaxan revenue. Based on the current run rate, we expect Xifaxan revenue to exceed $115 million in 2009. The bowel cleansing franchise, consisting of MoviPrep, Visicol and OsmoPrep generated revenue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/12/slxp-salix-pharmaceuticals-beats-expectation-on-xifaxans-strength/20386/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

